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Summary Coenzyme Q10 (CoQ10) has been widely commercially available in Japan as a
dietary and health supplement since 2001 and is used for the prevention of lifestyle-related
diseases induced by free radicals and aging. We evaluated CoQ10 supplements to ensure that
these supplements can be used effectively and safely. Commercially available products were
selected and assessed by the quality control tests specified in the Japanese Pharmacopoeia XV.
When the disintegration time of CoQ10 supplements was measured, a few tested supplements
did not completely disintegrate even after incubation in water for an hour at 37°C. In the
content test, many samples were well controlled. However, a few supplements showed low
recovery rates of CoQ10 as compared to manufacturer’s indicated contents. Among soft
capsule and liquid supplements, the reduced form of CoQ10 (H2CoQ10), as well as the oxidized
form, was detected by HPLC with electrochemical detector. The results for experimental
formulated CoQ10 supplements demonstrated that H2CoQ10 was produced by the interaction
of CoQ10 with vitamins E and/or C. From these results, we concluded that quality varied
considerably among the many supplement brands containing CoQ10. Additionally, we also
demonstrated that H2CoQ10 can be detected in some foods as well as in CoQ10 supplements.
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Introduction
It is well known that coenzyme Q (CoQ) serves as an
essential carrier for electron transport and proton translocation
in the mitochondrial respiratory chain [1]. Besides its role in
electron-transfer reactions, CoQ10 serves as a free radical
scavenger, thereby preventing oxidative damage in the
human body. Several researchers have pointed out that the
reduced form of CoQ10 (H2CoQ10) is an efficient scavenger
of lipid radicals and inhibitors of lipid peroxidation in low-
density lipoprotein [2, 3], biomembrane [4], and liposomes
[5, 6]. CoQ in the bodies of human beings is thought to be
provided by both dietary intake, from foods or dietary
supplements [7, 8], and de novo biosynthesis [9, 10]. Therefore,
decreases in the biosynthesis or intake of CoQ10 might affect
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the physiological action of CoQ10. In fact, decreased serum
levels of CoQ10 were observed in patients undergoing total
parenteral nutrition therapy without dietary intake [11], and
in patients [12, 13] and animals [14, 15] receiving HMG-
CoA reductase inhibitor (statin) administration.
CoQ10 was introduced into clinical therapy in 1974 in
Japan. Its generic name is ubidecarenone. Many clinical
trials showed that oral administration to patients was effective
for mild congestive heart failure symptoms such as edema,
lung congestion, and swollen liver. On the basis of these
clinical findings, CoQ10 was classified in the group of
cardiovascular drugs for metabolic disturbances. In 1991,
CoQ10, whose generic name is ubiquinone-10, was also
made available as an over-the-counter drug in pharmacies.
While sales of dietary and health supplement products have
been rapidly increasing in Japan, it is vital to supply quality-
controlled products for consumers. In 2001, the Ministry of
Health, Labour and Welfare in Japan permitted the use of
CoQ10 as a food additive as long as no claims were made about
its pharmacological effectiveness and application. Currently,
it is estimated that more than 200 kinds of CoQ10-containing
dietary and health supplements (CoQ10 supplements), produced
by more than 100 different manufacturers, are available. In
particular, CoQ10 supplements are used for the prevention of
lifestyle-related diseases induced by free radicals and aging.
However, the products may vary in quality. Because CoQ10
has a rather complicated chemical structure and possesses
several physical properties, such as low melting point,
hydrophobic nature, and light sensitivity, that do not favor
large-scale commercial production, highly sophisticated
techniques should be employed at all production stages to
obtain a satisfactory product [16]. Moreover, many Japanese
CoQ10 supplements also contain other components, e.g.,
vitamins, minerals, amino acids, antioxidative compounds, and
enzymes, in the same tablet, soft capsule, or other product.
Therefore, the chemical stability of CoQ10 supplements is
also an important point to be considered.
In this study, we evaluated the quality of commercially
available CoQ10 supplements to ensure that these supplements
can be used effectively and safely. In addition, to investigate
the distribution of CoQ10 in foods from a nutritional point of
view, we also measured both CoQ10 and H2CoQ10 contents in
selected foods.
Materials and Methods
Reagents
Authentic CoQ homologues from CoQ7 to CoQ11 were
kindly supplied by Nisshin Pharma Inc., Tokyo. High
performance liquid chromatography (HPLC) solvents and
ethanol were purchased (HPLC grade) from Wako Pure
Chemical Industries, Ltd., Osaka, Japan. All other chemicals
used were of analytical grade, available from commercial
suppliers.
CoQ10 supplements
CoQ10 supplements were commercially purchased from
pharmacies, health food stores, department stores, convenience
stores, and sport goods shops in the Kobe city area. Forms
tested in this study included tablet (TB), hard capsule
(HCP), soft capsule (SCP), granule (GN), liquid (LQ), jelly
(JL), and inclusion complex with γ-dextrin (ICD). The
quality control tests of CoQ10 supplements were completed
within 6 months before the product’s consume-by date.
CoQ10 supplements obtained for testing were preserved in
tight, light-resistant containers at room temperature until the
quality control tests were conducted.
Experimental manufacturing preparations for SCPs, a LQ,
and an HCP of “Formulas 1 to 5”
Experimental manufacturing products for 3 SCP forms, a
LQ form, and an HCP form of formulas 1 to 5 were kindly
provided by Shiseido Medical, Co., Ltd., Tokyo, Japan. The
detailed formulas of their components are shown in Table 1.
Quality control tests
Disintegration test—This test was performed using the
apparatus (Model TMB-81, Toyama Sangyo Co., Ltd.,
Osaka, Japan) and test conditions specified in the Japanese
Pharmacopoeia XV (J.P.XV). Water and the first (pH 1.2)
and the second (pH 6.8) fluids of the J.P.XV method
were used as the immersion solution at 37 ± 2°C. The
time required for each TB, HCP, and SCP to completely
disintegrate was recorded, and the mean disintegration time
was calculated. Complete disintegration is defined by the
J.P.XV as that state in which any residue of the unit, except
fragments of insoluble coating or capsule shell, remaining
Table 1. Experimental formulas of CoQ10 supplement forms of soft capsule, liquid, and hard capsule
Contents “Formula 1” “Formula 2” “Formula 3” “Formula 4” “Formula 5”
Intake form Soft capsule Soft capsule Soft capsule Liquid Hard capsule
Based Oil Safflower oil Safflower oil Olive oil — —
CoQ10 30 mg 10 mg 30 mg 30 mg 30 mg
V i t a m i n  E 1 0m g 3 0m g 1 0m g 1 0m g 1 0m g
Vitamin C 30 mg — 30 mg 30 mg 30 mgA. Kettawan et al.
J. Clin. Biochem. Nutr.
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on the screen (0.25–0.31 mm) of the test apparatus is a soft
mass having no palpably firm core.
Content test—All procedures for the content test of CoQ10
supplements were carried out in the dark.
i) Pre-preparation of CoQ10 supplements
TB and ICD products were crushed carefully in a mortar
to obtain a homogenous fine powder. This powder was
transferred completely to a 50-ml brown volumetric flask,
and about 30 ml of ethanol was added to the flask.
HCP and SCP products were carefully opened, the
contents were transferred completely to a brown 50-ml
volumetric flask, and about 30 ml of ethanol was added to
the flask. If ethanol-insoluble contents and/or fragments
were observed, these were sonicated on ice for 1 min with
output 3 to 5 (Ultrasonic Distruptor, Model UR-200P, Tomy
Seiko Co, Ltd., Tokyo, Japan).
In the case of LQ products, an aliquot of 5 ml of drink
solution was pipetted into a 50-ml brown volumetric flask
directly, and about 30 ml of ethanol was added to the flask.
For JL and GN products, an equivalent of 5 mg was weighed
accurately and dissolved in 10 ml of water and about 20 ml
of ethanol in a mortar to obtain a homogenous solution.
The solution was completely transferred to a brown 50-ml
volumetric flask.
ii) Preparation of CoQ10 supplements
After the ethanol solution was prepared as described
above, it was incubated for 10 min at 50°C and allowed to
stand for 10 min at room temperature. Then, the ethanol
solution was added to the flask again to scale up to 50 ml.
The solution was filtered with filter paper (No. 3) and diluted
with ethanol to adjust to a 10 µg/ml CoQ10-containing
ethanol solution. Finally, except for SCP products, an aliquot
of 10 µl of the ethanol solution was injected into the column
to determine H2CoQ10.
In the case of SCP products only, an aliquot of 0.5 ml of
10 µg/ml CoQ10-containing ethanol solution was pipetted
into a brown glass-stoppered centrifuged tube, and then
0.5 ml of distilled water, 1.5 ml of ethanol, and 5 ml of
n-hexane were added in turn. The mixture was shaken
vigorously reciprocally at a rate of 80 times per minute for
10 min and centrifuged at 500 g for 10 min. This extraction
procedure was repeated three times. Subsequently, the
combined n-hexane layer was concentrated in vacuo under a
stream of nitrogen. The resulting residue was dissolved in
0.5 ml of ethanol, and an aliquot of 10 µl of the ethanol
solution was injected into the column to determine H2CoQ10.
Separately, an aliquot of 10 µl of 0.25% sodium boro-
hydride solution (0.25 mg/ml water) was added to 0.4 ml of
the ethanol and the mixture allowed to stand for 10 min at
room temperature. An aliquot of 10 µl of the solution was
injected into the column to determine total CoQ10, the sum of
reduced and oxidized CoQ10.
iii) HPLC conditions for determination of CoQ10 and H2CoQ10
The content of CoQ10 supplements was determined by an
HPLC method with electrochemical detection (ECD), as
previously described [17]. Authentic CoQ homologues from
CoQ7 to CoQ11 were prepared by dissolution in ethanol to
yield concentrations of 10 µg/ml. Authentic CoQ homologues
were freshly prepared from the corresponding CoQ, adding
25 µg of sodium borohydride (10 µl of a 0.25% solution of
sodium borohydride in water) to give a concentration of
1 µg/ml prior to HPLC-ECD analysis.
Food samples
Food samples were obtained from local food stores or
supermarkets in the Kobe city area. All food items were
analyzed raw, without freezing. In some cases, samples of
the same food were collected on separate days.
Measurement of CoQ homologue contents in foods
Food samples were homogenized with distilled water at 4°C
using a Polytron homogenizer (Type PT 10/35; Kinematica,
Lucerne, Switzerland) at a setting of 7 to 30 seconds. The
final volume of the homogenate was adjusted so as to
contain about 1 to 2 µg of H2CoQ10. An aliquot of 0.5 ml of
the homogenate was pipetted into a brown glass-stoppered
centrifuged tube, and then 2 ml of ethanol and 5 ml of n-
hexane were added. The solution was extracted as described
above for SCP products, and the contents of H2CoQs and
CoQs were determined by HPLC-ECD [17].
Results
Internal profile for SCP forms of CoQ10 supplements
Among CoQ10 supplements, SCP is the most common
commercially available intake form in Japan. According to
the United States Pharmacopoeia, SCPs (sometimes called
soft gelatin capsules or softgels) are filled with liquid
contents in most cases. Typically, CoQ10 is dissolved or
suspended in a liquid vehicle such as vegetable oil or the
lower-molecular-weight polyethylene glycols.
First, we assessed the internal profile of different SCP CoQ10
supplement products. Most samples showed the typical
internal profile of SCPs. However, as shown in Fig. 1, in a few
SCPs, CoQ10 crystallized itself inside and existed in the solid
state but not the lipid-soluble form. Moreover, a certain SCP
did not show the uniform distribution of CoQ10 in the capsule.
Disintegration tests for TB, HCP, SCP, and ICD forms of
CoQ10 supplements
According to the disintegration test specified in the J.P.XV,
TB supplements should disintegrate with water as the
immersion fluid within 30 min after operating the apparatus.
For both HCP and SCP supplements, the time limit is 20 min.
Although ICD is the inclusion complex form of CoQ10 and γ-Quality Control Tests of Dietary CoQ10 Supplements
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dextrin, the disintegration time is not specified by J.P.XV.
When we measured the disintegration time of 2 kinds of
CoQ10-containing over-the-counter (OTC) drugs as controls,
their disintegration times were 3.8 min for OTC-TB and
4.6 min for OTC-SCP, respectively. OTC drugs were well
controlled and met the necessary requirements specified in
the J.P.XV (Table 2).
For CoQ10 supplements, as shown in Table 2, the dis-
integration time was 3.2 min to >60 min for TBs, 3.2 min to
23.8 min for HCPs, 5.6 min to >60 min for SCPs, and
8.8 min to 32.5 min for ICDs; considerable differences were
observed among the many supplements. In particular, the
disintegration time of about half of the SCPs was more than
60 min. Among the different forms of CoQ10 supplements,
the disintegration performance of ICDs was not always faster
than that of other forms. Moreover, as tested supplements
might be enteric-coated tablets, we also carried out the
disintegration tests again for the first fluid, simulated gastric
fluid (pH 1.2), and the second fluid, simulated intestinal
fluid (pH 6.8). However, the results did not differ from those
of water as the immersion fluid.
Content tests for CoQ10 supplements
Although the J.P.XV specifies the HPLC-UV method as
the identification and content test for ubidecarenone, we
applied the HPLC-ECD method as described in Materials
and Methods instead because this method can measure both
the reduced and oxidized forms of CoQ10 and shows higher
sensitivity than the HPLC-UV method does.
Of course, the content of the over-the-counter drugs
used as controls was well controlled within an extremely
limited range (99–100%). Most CoQ10 supplements showed a
content value of more than 80%. However, a few supplements
exhibited low recovery rates of CoQ10 as compared to
manufacturers’ indicated contents. Moreover, in several SCP
and LQ products, H2CoQ10 as well as CoQ10 was detected.
Interestingly, in LQ-6, as shown in Table 3, CoQ10 was
Fig. 1. Internal appearance of soft capsule forms of CoQ10-
supplements. (A) Crystallized CoQ10; the yellowed
compound is crystallized CoQ10. (B) Typical soft capsule
appearance; CoQ10 distributes uniformly in the soft
capsule.
Table 2. The disintegration time of CoQ10 supplements, tablets,
hard capsules, soft capsules, and inclusion complex with
γ-dextrin
Samples*
Disintegration Time (min)
Water
First fluid 
(pH 1.2, J.P.XV)
Second fluid 
(pH 6.8, J.P.XV)
OTC-TB 3.8 ± 0.2 4.1 ± 0.4 6.0 ± 0.4
OTC-SCP 4.6 ± 0.1 6.8 ± 0.1 9.8 ± 0.5
TB-1 11.3 ± 0.9 16.5 ± 0.6 11.1 ± 0.7
TB-2 3.2 ± 0.4 3.6 ± 1.0 2.4 ± 0.1
TB-3 10.7 ± 0.4 12.8 ± 0.6 13.1 ± 0.3
TB-4 11.1 ± 0.1 12.1 ± 0.1 13.4 ± 0.1
TB-5 >60 >60 >60
TB-6 55.2 ± 0.9 56.4 ± 0.4 55.9 ± 0.8
TB-7 4.6 ± 0.6 3.3 ± 0.0 4.1 ± 0.8
TB-8 31.5 ± 2.6 32.1 ± 13.1 33.7 ± 3.9
TB-9 23.4 ± 0.7 32.8 ± 0.5 21.4 ± 0.4
TB-10 11.8 ± 3.2 11.8 ± 1.9 14.8 ± 4.2
TB-11 17.5 ± 2.8 19.6 ± 1.3 16.5 ± 2.0
TB-12 >60 >60 >60
TB-13 18.3 ± 0.2 18.6 ± 0.5 18.8 ± 0.6
TB-14 56.7 ± 1.3 53.4 ± 0.8 58.7 ± 1.6
TB-15 19.6 ± 1.4 18.9 ± 1.5 18.7 ± 1.6
TB-16 9.3 ± 1.0 11.3 ± 0.3 11.6 ± 0.5
TB-17 18.8 ± 1.0 18.6 ± 0.8 25.1 ± 1.9
HCP-1 6.9 ± 1.9 7.2 ± 1.5 17.6 ± 0.4
HCP-2 10.8 ± 0.6 9.9 ± 0.3 11.9 ± 0.7
HCP-3 3.2 ± 0.2 4.0 ± 0.4 3.6 ± 0.3
HCP-4 23.8 ± 3.0 22.5 ± 3.8 13.9 ± 0.9
HCP-5 4.9 ± 0.9 3.2 ± 0.1 5.3 ± 0.9
SCP-1 10.2 ± 1.0 12.9 ± 1.0 11.2 ± 1.0
SCP-2 5.6 ± 0.2 5.6 ± 0.5 10.7 ± 0.5
SCP-3 47.2 ± 1.5 54.9 ± 2.8 57.2 ± 0.9
SCP-4 >60 >60 >60
SCP-5 >60 44.0 ± 2.5 52.7 ± 2.0
SCP-6 >60 >60 >60
SCP-7 >60 >60 >60
SCP-8 41.0 ± 0.9 40.7 ± 2.5 32.6 ± 1.9
SCP-9 19.0 ± 1.5 21.5 ± 0.5 13.8 ± 0.9
SCP-10 >60 >60 >60
SCP-11 14.8 ± 0.7 16.9 ± 1.5 14.0 ± 1.6
SCP-12 >60 >60 >60
SCP-13 11.4 ± 0.7 7.8 ± 0.3 8.0 ± 0.7
ICD-1 32.5 ± 3.4 30.8 ± 2.7 41.6 ± 2.1
ICD-2 29.9 ± 2.1 41.3 ± 1.1 28.1 ± 1.5
ICD-3 12.1 ± 0.8 15.6 ± 1.9 11.6 ± 0.9
ICD-4 30.0 ± 2.2 29.8 ± 0.7 31.4 ± 2.4
ICD-5 26.4 ± 3.3 36.4 ± 2.7 25.1 ± 2.8
ICD-6 8.8 ± 0.7 12.1 ± 0.9 7.6 ± 0.6
*OTC, over-the-counter drug; TB, tablet; HCP, hard capsule; SCP,
soft capsule; ICD, inclusion complex with γ-dextrin. Data are
expressed as means ± SD (n = 6).A. Kettawan et al.
J. Clin. Biochem. Nutr.
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Table 3. Content test of CoQ10 supplements, tablets, hard capsules, soft capsules, liquids, jellies,
granules, and inclusion complex with γ-dextrin
CoQ10-supplements*
Content (mg)
Labeled CoQ10 H2CoQ10 (%)** Total CoQ10 (%)***
OTC-TB 10 ND**** 100.5 ± 0.1 (100)
OTC-SCP 10 ND 99.4 ± 0.2 (99)
TB-1 10 ND 9.6 ± 0.3 (96)
TB-2 6.3 ND 3.4 ± 0.1 (54)
TB-3 11.1 ND 9.4 ± 0.5 (85)
TB-4 1.7 ND 1.6 ± 0.1 (94)
TB-5 5 ND 4.6 ± 0.2 (92)
TB-6 16.7 ND 17.2 ± 0.4 (103)
TB-7 10 ND 9.3 ± 0.4 (93)
TB-8 60 ND 55.6 ± 1.4 (93)
TB-9 20 ND 20.0 ± 0.5 (100)
TB-10 0.34 ND 0.4 ± 0.01 (118)
TB-11 3.75 ND 3.7 ± 0.3 (99)
TB-12 0.83 ND 0.9 ± 0.1 (108)
H C P - 19 0N D 9 2 . 3 ± 0.5 (103)
H C P - 28 0N D4 . 2 ± 0.1 (5)
H C P - 33 0N D 2 8 . 7 ± 1.47 (96)
H C P - 46 0N D 5 9 . 3 ± 1.3 (99)
H C P - 53 0N D 3 0 . 8 ± 0.9 (103)
SCP-1 33.3 5.8 ± 0.5 (17) 33.8 ± 1.4 (101)
SCP-2 30 14.1 ± 1.0 (46) 30.6 ± 0.9 (102)
SCP-3 30 7.0 ± 0.8 (22) 31.0 ± 1.2 (103)
SCP-4 30 13.5 ± 0.4 (44) 31.1 ± 0.7 (104)
SCP-5 30 13.7 ± 0.7 (52) 26.4 ± 1.0 (88)
SCP-6 35 1.6 ± 0.5 (4) 35.8 ± 0.8 (102)
SCP-7 30 1.8 ± 0.03 (6) 28.0 ± 0.6 (94)
SCP-8 30 25.3 ± 0.7 (88) 28.8 ± 0.6 (96)
SCP-9 150 6.2 ± 0.4 (5) 120.8 ± 3.8 (80)
SCP-10 30 1.4 ± 0.1 (4) 30.7 ± 0.3 (102)
SCP-11 30 3.8 ± 0.7 (12) 30.7 ± 0.9 (102)
SCP-12 50 ND 49.6 ± 1.0 (99)
SCP-13 30 ND 31.1 ± 0.4 (104)
SCP-14 30 5.9 ± 0.7 (19) 31.0 ± 0.5 (103)
SCP-15 10 ND 10.1 ± 0.1 (101)
SCP-16 10 ND 10.0 ± 0.1 (100)
SCP-17 10 1.1 ± 0.2 (14) 8.0 ± 0.6 (80)
SCP-18 30 5.2 ± 0.4 (16) 31.4 ± 0.4 (105)
SCP-19 30 2.6 ± 0.7 (9) 30.4 ± 0.6 (101)
SCP-20 45 3.9 ± 0.2 (8) 46.5 ± 0.7 (103)
SCP-21 15 8.0 ± 0.5 (53) 14.9 ± 0.6 ( 99)
SCP-22 30 3.4 ± 0.2 (12) 27.2 ± 0.9 ( 91)
SCP-23 20 0.9 ± 0.1 (4.2) 20.2 ± 1.1 (101)
SCP-24 60 ND 58.0 ± 4.1 (97)
SCP-25 0.25 0.04 ± 0.1 (16) 0.2 ± 0.1 (96)
LQ-1 40 ND 41.4 ± 1.9 (104)
LQ-2 30 ND 31.7 ± 1.4 (106)
LQ-3 30 ND 32.5 ± 0.3 (108)
LQ-4 1 ND 1.0 ± 0.03 (100)
LQ-5 50 12.3 ± 2.4 (24) 52.1 ± 0.8 (104)
LQ-6 — 5.2 ± 0.1 (—) 5.2 ± 0.1 (—)
JL-1 30 ND 29.3 ± 0.1 (98)
JL-2 50 ND 61.5 ± 4.6 (123)
GN-1 30 ND 28.5 ± 0.3 (95)
GN-2 30 ND 30.4 ± 0.2 (101)
GN-3 30 ND 30.2 ± 0.2 (101)
GN-4 30 ND 30.1 ± 0.1 (100)
ICD-1 3.75 as ICD ND 1.0 ± 0.01 (27)
ICD-2 84 as ICD ND 10.4 ± 0.3 (12)
ICD-3 18 as ICD 2.0 ± 0.6 (50) 3.9 ± 0.72 (22)
ICD-4 100 as ICD ND 21.8 ± 1.4 (22)
ICD-5 12.5 as ICD ND 0.9 ± 0.1 (7)
ICD-6 100 as ICD ND 22.8 ± 0.1 (23)
*OTC, over-the-counter drug; TB, tablet; HCP, hard capsule; SCP, soft capsule; LQ, liquid; JL, jelly; GN, granule; ICD,
inclusion complex with γ-dextrin. Data are expressed as means ± SD (n = 6).
** [H2CoQ10/total CoQ10 (sum of CoQ10 and H2CoQ10)] × 100.
*** [Sum of CoQ10 and H2CoQ10] × 100.
****Not detected.Quality Control Tests of Dietary CoQ10 Supplements
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recovered entirely as the reduced form, H2CoQ10.
ICD is the inclusion complex form of CoQ10 and γ-
dextrin. The purposes of developing this inclusion complex
with CoQ10 seem to be reduction of instability to light and
enhancement of bioavailability. However, the manufacturer’s
indicated contents were mentioned and listed on the package
only as “CoQ10 inclusion complexes with γ-dextrin.” Thus,
the CoQ10 content of the product was uncertain. As shown in
Table 3, we estimated that the inclusion ratio of CoQ10 to γ-
dextrin in the tested ICD will be in the range from 5% to
30%.
H2CoQ10 production in the SCP and LQ forms of CoQ10
supplements
We recognized that all CoQ10 supplements in which
H2CoQ10 was detected contained vitamin E (α-tocopherol)
and/or vitamin C (ascorbic acid). Therefore, we presumed
that H2CoQ10 might be produced by the interaction of CoQ10
with vitamin E and/or vitamin C. To confirm this possibility,
we prepared the experimental formulas listed in Table 1.
As shown in Fig. 2, co-existence of CoQ10 and vitamin E
and/or vitamin C produced reduction of CoQ10 to H2CoQ10 in
SCPs and a LQ. The content ratio of vitamin E to CoQ10 was
also important. The existence of safflower oil in SCPs was
also an essential condition for production of H2CoQ10 from
CoQ10 in SCPs. In particular, a LQ form of CoQ10 that co-
existed with vitamin E and vitamin C exhibited a high ratio
of the reduced form to total CoQ10 in a time-dependent
manner. In an HCP, however, the reduction of CoQ10 to
H2CoQ10 was not observed even if CoQ10 co-existed with
vitamin E and C.
H2CoQ10 and CoQ10 contents in foods
To determine the dietary intake of H2CoQ10 as well as
CoQ10 in human beings, we analyzed the CoQ10 contents of
raw foods. Table 4 shows both the CoQ10 and H2CoQ10
contents of meats and vegetables. The greater part of the
CoQ homologues in meats and vegetables was CoQ10.
Moreover, H2CoQ10 as well as CoQ10 was detected in all
examined samples. In particular, squid and eel meats showed
high ratios of the reduced form, H2CoQ10, as compared to
other animal products. H2CoQ9 and CoQ9 were also detected
in small amounts in beef, pork, and chicken.
Discussion
Although CoQ10 supplements have not been required
to meet the same rigorous product quality performance
standards as medicines do, impaired product performance,
such as failure to disintegrate in the gastrointestinal tract,
might limit the absorption of CoQ10. However, standardized
guidelines and methods for assessing the quality control of
dietary and health supplements have not been established
in Japan. So, we applied the Japanese Pharmacopoeial
Convention General Tests to evaluate the quality of CoQ10
supplements in this study.
Externally administered CoQ10 appears to be converted to
H2CoQ10 in the human body and then to act as an antioxidant
against lipid peroxidation. In fact, a CoQ10 supplement
given to a human increases the serum level of H2CoQ10
as well as CoQ10 [ 18]. The enzymes responsible for the
reduction of CoQ10 to H2CoQ10 have been reported to be not
only mitochondrial respiratory enzymes but also NADPH-
CoQ reductase [19–21], NAD(P)H:quinone oxidoreductase
1 (NQO1, DT-diaphorase) [22, 23], thioredoxin reductase
[24], and lipoamide dehydrogenase [25, 26]. CoQ in the
human body is thought to be provided by both dietary intake
from foods and/or dietary supplements and biosynthesis de
novo.
In this study, we tested two quality control tests, dis-
integration and content tests. The disintegration profile and
content test are thought to be essential parameters relative
to absorption and intake efficacy. Many commercially
available CoQ10 supplements in Japan were well controlled
and met the requirements specified by J.P.XV. However, a
few products exhibited insufficient quality performance. In
particular, the disintegration of many SCPs required more
than 60 min. The gelatin shell of an SCP is somewhat thicker
than that of an HCP shell and is plasticized by the addition
of a polyol such as sorbitol or glycerol. The ratio of dry
plasticizer to dry gelatin determines the hardness of the
shell and may be varied to accommodate environmental
conditions as well as the nature of the contents. Therefore,
the disintegration time of SCPs may have a higher score than
that of HCPs. In this study, we demonstrated that the quality
Fig. 2. H2CoQ10 produced by interaction of CoQ10 with vitamins
C and/or E in soft capsule and liquid. Each formula is
shown in Table 1.A. Kettawan et al.
J. Clin. Biochem. Nutr.
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of the many supplement products containing CoQ10 in Japan
varies considerably, and thus, we recommend introducing
simple quality control tests for CoQ10 supplements.
Among CoQ10 supplements, in SCPs and LQs, H2CoQ10
as well as CoQ10 was detected by the HPLC-ECD method.
The results for experimentally formulated CoQ10 supplements
suggested that H2CoQ10 was produced by the interaction of
CoQ10 with vitamins E and/or C. Moreover, although H2CoQ10
is unstable when exposed to air, and can easily be oxidized
into oxidized CoQ, chemically unstable H2CoQ10 is thought
to exist in the body to serve as an antioxidant. Recently,
Yan et al. have reported [27] that dietary supplementation
with H2CoQ10 decreased the degree of senescence in middle-
aged SAMP1 mice. H2CoQ10 produced by the interaction
of CoQ10 with vitamins E and/or C, therefore, may exert
beneficial effects in the human body.
Many investigators have reported that exogenous CoQ10
exhibits useful health effects. If humans consume H2CoQ10
as well as CoQ10 in meals every day, foods containing
H2CoQ10 and CoQ10 might have some physiological activities.
Therefore, it is important to investigate the distribution of
these substances in foods. Some investigators have reported
the CoQ homologue contents in foods. However, they could
not analyze reduced forms of CoQ homologues because of
the HPLC-UV method and insufficient sensitivity. In our
study, we measured the distribution of both CoQ10 and
H2CoQ10 in food items. The results clarify that humans
consume not only CoQ10 but also H2CoQ10 from foods. In
other words, the present study confirms the human intake of
H2CoQ10 in daily foods and dietary CoQ10 supplements.
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